



C9C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	Levi, et al.	Examiner:	Raymond J. Henley III
Serial No.:	10/076,204	Group Art Unit:	1614
Confirmation No:	8595	Docket:	955-16
Filed:	February 13, 2002	Dated:	May 13, 2005
Patent No.:	6,884,809 B2	Issue Date:	April 26, 2005
For:	Method and Compositions for Reducing Cardiac Dysfunctions with a Selective Histamine H ₃ Receptor Agonist		

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Certificate
MAY 23 2005

of Correction

I hereby certify this correspondence is being deposited
with the United States Postal Service as first class mail,
postpaid in an envelope addressed to Commissioner for
Patents, PO Box 1450, Alexandria, VA 22313-1450

on May 13, 2005 Signature Julie A. Watts

REQUEST FOR CERTIFICATE OF CORRECTION OF
PATENT PURSUANT TO 37 C.F.R. §1.322

Sir:

Please issue a Certificate of Correction in accordance with 37 C.F.R. §1.322 to correct the errors in the patent as set forth hereinbelow and on the enclosed copy of Patent Office Form PTO-1050. Form PTO-1050 is attached hereto in duplicate with at least one copy being suitable for printing.

IN THE CLAIMS:

In Column 16, Line 53,

now reads "reducing cardiac dysfunctions ...", and
should read --reducing cardiac dysfunction ...--

In Column 16, Line 55,

now reads "patholoaical excess of noreninephrine
release,", and should read -- pathological
excess of norepinephrine release,...--

In Column 16, Line 56,

now reads "comprising a administering...", and
should read --comprising administering--

In Column 17, Line 1,

now reads "S- α -chloromethylhistamine ..." and
should read --S- α -chloromethylhistamine ...--

In Column 17, Line 20,

now reads "The method according to claim 1,...",
and should read --The method according to claim
10, ...--

In Column 17, Line 23,

now reads "agonist inhibits the Na⁺ H⁺...", and
should read --agonist inhibits the Na⁺/H⁺ ...--

In Column 17, Line 25,

now reads "agonist inhibits the Na⁺ H⁺
exchanger...", and should read -- agonist inhibits
the Na⁺/H⁺ exchanger ...--

In Column 17, Line 36,

now reads "N-type Ca²⁺ channel.", and should read
-- N-type Ca²⁺ channel.--

In Column 18, Line 1,

now reads "inhibiting the Na⁺ H⁺ exchanger...",
and should read -- inhibiting the Na⁺/H⁺ exchanger
...--

In Column 18, Line 4,

now reads "histamine H³ receptor agonist.", and
should read -- histamine H₃ receptor agonist.--

In Column 18, Line 13,

now reads "methylbistamine,...", and should read --
methyhlhistamine, ...--

In Column 18, Line 41,


now reads "an anti-arrhythmic,...", and should read
-- an anti-arrhythmic, ...--

The above-identified errors occurred through no fault of the Applicants. Accordingly, no
fee is enclosed.

Application Serial No: 10/076,204
Filing Date: February 13, 2002
Docket No. 955-16
Page 3 of 3

It is respectfully requested that a Certificate of Correction be issued to correct the errors in the above-identified patent.

Respectfully submitted,


Edna I. Gergel, Ph.D.
Registration No. 50,819
Agent for Applicants

HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791
Tel, 516-822-3550
Fax. 516-822-3582
EIG:jlw
204708_1

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 6,884,809 B2
DATED : May 13, 2005
INVENTOR(S) : Levi, et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

IN THE CLAIMS:

<u>In Column 16, Line 53,</u>	now reads “reducing cardiac dysfunctions ...”, and should read --reducing cardiac dysfunction ...--
<u>In Column 16, Line 55,</u>	now reads “patholoaical excess of noreninephrine release, ...”, and should read -- pathological excess of norepinephrine release,...--
<u>In Column 16, Line 56,</u>	now reads “comprising a administering...”, and should read --comprising administering--
<u>In Column 17, Line 1,</u>	now reads “S- α -chloromethylhistarnine ...” and should read --S- α -chloromethylhistamine ...--
<u>In Column 17, Line 20,</u>	now reads “The method according to claim 1,...”, and should read --The method according to claim 10, ...--
<u>In Column 17, Line 23,</u>	now reads “agonist inhibits the Na ⁺ H ⁺ ...”, and should read --agonist inhibits the Na ⁺ /H ⁺ ...--
<u>In Column 17, Line 25,</u>	now reads “agonist inhibits the Na ⁺ H ⁺ exchanger...”, and should read -- agonist inhibits the Na ⁺ /H ⁺ exchanger--

MAILING ADDRESS OF SENDER
Edna I. Gergel, Ph.D.
HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791

PATENT NO. 6,884,809 B2

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 6,884,809 B2

DATED : May 13, 2005

INVENTOR(S) : Levi, et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

In Column 17, Line 36, now reads "N-type Ca²⁺ channel.", and should read -- N-type Ca²⁺ channel.--

In Column 18, Line 1, now reads "inhibiting the Na⁺ H⁺ exchanger...", and should read -- inhibiting the Na⁺/H⁺ exchanger ...--

In Column 18, Line 4, now reads "histamine H³ receptor agonist.", and should read -- histamine H₃ receptor agonist.--

In Column 18, Line 13, now reads "methylbistamine,...", and should read -- methylhistamine, ...--

In Column 18, Line 41, now reads "an anti-arrhythmic,...", and should read -- an anti-arrhythmic, ...--

MAILING ADDRESS OF SENDER

Edna I. Gergel, Ph.D.
HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791

PATENT NO. 6,884,809 B2

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 6,884,809 B2
DATED : May 13, 2005
INVENTOR(S) : Levi, et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

IN THE CLAIMS:

<u>In Column 16, Line 53,</u>	now reads "reducing cardiac dysfunctions ...", and should read --reducing cardiac dysfunction ...--
<u>In Column 16, Line 55,</u>	now reads "patholoaical excess of noreninephrine release, ...", and should read -- pathological excess of norepinephrine release,...--
<u>In Column 16, Line 56,</u>	now reads "comprising a administering...", and should read --comprising administering ...--
<u>In Column 17, Line 1,</u>	now reads "S- α -chloromethylhistamine ..." and should read --S- α -chloromethylhistamine ...--
<u>In Column 17, Line 20,</u>	now reads "The method according to claim 1,...", and should read --The method according to claim 10, ...--
<u>In Column 17, Line 23,</u>	now reads "agonist inhibits the Na ⁺ H ⁺ ...", and should read --agonist inhibits the Na ⁺ /H ⁺ ...--
<u>In Column 17, Line 25,</u>	now reads "agonist inhibits the Na ⁺ H ⁺ exchanger...", and should read -- agonist inhibits the Na ⁺ /H ⁺ exchanger ...--

MAILING ADDRESS OF SENDER
Edna I. Gergel, Ph.D.
HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791

PATENT NO. 6,884,809 B2

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 6,884,809 B2
DATED : May 13, 2005
INVENTOR(S) : Levi, et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

<u>In Column 17, Line 36,</u>	now reads "N-type Ca ²⁺ channel.", and should read -- N-type Ca ²⁺ channel.--
<u>In Column 18, Line 1,</u>	now reads "inhibiting the Na ⁺ H ⁺ exchanger...", and should read -- inhibiting the Na ⁺ /H ⁺ exchanger ...--
<u>In Column 18, Line 4,</u>	now reads "histamine H ³ receptor agonist.", and should read -- histamine H ₃ receptor agonist.--
<u>In Column 18, Line 13,</u>	now reads "methylbistamine,...", and should read -- methylhistamine, ...--
<u>In Column 18, Line 41,</u>	now reads "an anti-arrhythmic,...", and should read -- an anti-arrhythmic, ...--

MAILING ADDRESS OF SENDER
Edna I. Gergel, Ph.D.
HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791

PATENT NO. 6,884,809 B2